Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer


Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Edwin (Ed) Tucker, M.D., as Chief Medical Officer (CMO), effective immediately. Dr. Tucker brings to Goldfinch Bio over 30 years of clinical experience across a variety of therapeutic areas and early- and late-stage companies. Dr. Tucker has successfully advanced several programs through clinical development and regulatory approval. In his new role, he will join Goldfinch Bio’s executive team and provide leadership and direction across clinical development, pharmacovigilance, quality and medical affairs efforts. “We’re delighted to welcome Ed to Goldfinch Bio. His deep expertise across clinical development and related functions makes him a tremendous and timely addition to our team,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024. Ed’s insights will be critical as we review all results and determine the most efficient next steps to bring these novel treatments to patients. We look forward to Ed’s valuable contributions as we continue to grow as a company and pursue our mission of delivering disease-modifying precision medicines to bring hope and renewed quality of life for people living with kidney diseases.” Goldfinch Bio’s lead clinical candidate, GFB-887, a podocyte-targeting small molecule inhibitor of TRPC5, is currently in a Phase 2 trial (TRACTION-2) for the treatment of focal segmental glomerulosclerosis…

Excerpt only …
Source : Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.